Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence.
Ruggiero AngeloVincenzo PiconeFabrizio MartoraGabriella FabbrociniMatteo MegnaPublished in: Clinical, cosmetic and investigational dermatology (2022)
Interleukin (IL)-23 inhibitors, guselkumab, risankizumab, and tildrakizumab, represent the latest class of biologics approved for the treatment of moderate-to-severe psoriasis. Since their approval numerous real-life studies were published on anti-IL-23 use in routine clinical practice. Indeed, real-life data are important to improve the dermatological decision-making process, including patients who are typically excluded from clinical trials, such as subjects suffering from several comorbidities, subjects on polypharmacy, as well as multifailure patients. Herein, we performed a comprehensive literature review about real-life data available on guselkumab, risankizumab, and tildrakizumab. Real-life data of anti-IL-23 seem to confirm the promising results of IL-23 shown by clinical trials, highlighting the efficacy and safety profiles of this new class of biologics also in clinical practice.
Keyphrases
- clinical practice
- clinical trial
- end stage renal disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- emergency department
- peritoneal dialysis
- randomized controlled trial
- big data
- systematic review
- early onset
- patient reported outcomes
- data analysis
- patient reported
- combination therapy
- atopic dermatitis